Understand the source comparison
GHRP-6 Acetate Alternatives 2026 Best: Peptide Comparison
Before selecting an alternative, match the compound's receptor profile and half-life to your study's endpoints. Here's how the top options compare. GHRP-6 Acetate GHS-R1a + CD36 + ghrelin 20–30 minutes 3–4× daily Strong (65–75% subjects) Baseline (1.0×) Effect
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before selecting an alternative, match the compound's receptor profile and half-life to your study's endpoints. Here's how the top options compare.
- GHRP-6 Acetate
- GHS-R1a + CD36 + ghrelin
- 20–30 minutes
- 3–4× daily
- Strong (65–75% subjects)
- Baseline (1.0×)
- Effective but limited by short half-life and high appetite stimulation. Replaced in most 2026 protocols
- Hexarelin
- GHS-R1a (high affinity)
- 60–90 minutes
- 2× daily
- Moderate (30–40% subjects)
- 3–4× higher
- Best for potency-focused studies where twice-daily dosing is manageable. Superior GH release per dose
- CJC-1295/Ipamorelin
- GHS-R1a (Ipamorelin) + GHRH (CJC)
- 6–8 days (CJC)
- 1–2× weekly
- Minimal (<10% subjects)
- 2–3× sustained
- Cleanest option for metabolic research. Minimal off-target effects, simplified dosing, lowest appetite interference
- MK-677 (Ibutamoren)
- GHS-R1a (selective)
- 24 hours
- 1× daily (oral)
- Mild-moderate (sustained)
- 1.5–2× sustained
- Only oral option. Eliminates injection logistics, best for compliance-sensitive studies, moderate appetite effect